{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T15:44:30Z","timestamp":1766159070951,"version":"3.44.0"},"reference-count":32,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jpharmsci.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.xphs.2022.12.013","type":"journal-article","created":{"date-parts":[[2022,12,21]],"date-time":"2022-12-21T02:05:21Z","timestamp":1671588321000},"page":"877-883","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["The Pharmacokinetics and Pharmacodynamics of A Novel Recombinant Activated Human Factor VII, GEN-0828, in Hemophilia B Mice"],"prefix":"10.1016","volume":"112","author":[{"given":"Yu-lu","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao-xia","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li-yun","family":"Niu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ya","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui","family":"GAN","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhuo-na","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jian","family":"LI","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Su-xiang","family":"Feng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gui-fang","family":"Dou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruo-lan","family":"Gu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhi-yun","family":"Meng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.xphs.2022.12.013_bib0001","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S0021-9258(19)70127-6","article-title":"Isolation and characterization of human factor VII. Activation of factor VII by factor Xa","volume":"256","author":"Bajaj","year":"1981","journal-title":"J Biol Chem"},{"key":"10.1016\/j.xphs.2022.12.013_bib0002","series-title":"Blood Coagulation Factors: Their Complementary DNAs, Genes and expression. In: Hemostasis and Thrombosis","first-page":"135","author":"Greenberg","year":"2001"},{"key":"10.1016\/j.xphs.2022.12.013_bib0003","doi-asserted-by":"crossref","first-page":"40919","DOI":"10.18632\/oncotarget.7261","article-title":"A plasma proteolysis pathway comprising blood coagulation proteases","volume":"7","author":"Yang","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.xphs.2022.12.013_bib0004","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.1053\/j.seminhematol.2008.03.013","article-title":"Further understanding of recombinant activated factor VII mode of action","volume":"45","author":"Monroe","year":"2008","journal-title":"Semin Hematol"},{"key":"10.1016\/j.xphs.2022.12.013_bib0005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1182\/blood.V76.1.1.1","article-title":"Surface-dependent reactions of the vitamin K-dependent enzyme complexes","volume":"76","author":"Mann","year":"1990","journal-title":"Blood"},{"key":"10.1016\/j.xphs.2022.12.013_bib0006","doi-asserted-by":"crossref","first-page":"2909","DOI":"10.1042\/BCJ20190595","article-title":"A candidate activation pathway for coagulation factor VII","volume":"476","author":"Misenheimer","year":"2019","journal-title":"Biochem J"},{"key":"10.1016\/j.xphs.2022.12.013_bib0007","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1016\/j.thromres.2014.12.018","article-title":"Enhanced pharmacokinetics of factor VIIa as a monomeric Fc fusion","volume":"135","author":"Salas","year":"2015","journal-title":"Thromb Res"},{"key":"10.1016\/j.xphs.2022.12.013_bib0008","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1542\/pir.34.7.289","article-title":"Hemophilia: in review","volume":"34","author":"Zimmerman","year":"2013","journal-title":"Pediatr Rev"},{"key":"10.1016\/j.xphs.2022.12.013_bib0009","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1046\/j.1365-2516.1998.00209.x","article-title":"A randomized, double-blind comparison of two dosage levels of recombinant factor VIIa in the treatment of joint, muscle and mucocutaneous haemorrhages in persons with haemophilia A and B, with and without inhibitors","volume":"4","author":"Lusher","year":"1998","journal-title":"Haemophilia"},{"key":"10.1016\/j.xphs.2022.12.013_bib0010","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.thromres.2009.11.027","article-title":"Recombinant coagulation factor VIIa from molecular to clinical aspects of a versatile haemostatic agent","volume":"125","author":"Persson","year":"2010","journal-title":"Thromb Res"},{"key":"10.1016\/j.xphs.2022.12.013_bib0011","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s12878-018-0126-z","article-title":"Recombinant activated factor \u2166 (rF\u2166a) in refractory haemorrhage for non-haemophiliacs: an eleven-year singlecentre experience","volume":"18","author":"Shah","year":"2018","journal-title":"BMC Hematol"},{"key":"10.1016\/j.xphs.2022.12.013_bib0012","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1177\/1089253217739689","article-title":"Coagulation management during liver transplantation: use of fibrinogen concentrate, recombinant activated factor \u2166, prothrombin complex concentrate, and antifibrinolytics","volume":"22","author":"Chow","year":"2018","journal-title":"Semin Cardiothorac Vasc Anesth"},{"key":"10.1016\/j.xphs.2022.12.013_bib0013","first-page":"14","article-title":"The action of high-dose factor VIIa (FVIIa) in a cell-based model of hemostasis","volume":"49","author":"Hoffman","year":"2003","journal-title":"Dis Mon"},{"key":"10.1016\/j.xphs.2022.12.013_bib0014","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1182\/blood-2003-07-2287","article-title":"Recombinant factor VIIa restores aggregation of alphaIIbbeta3-deficient platelets via tissue factor-independent fibrin generation","volume":"103","author":"Lisman","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.xphs.2022.12.013_bib0015","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1111\/jth.12409","article-title":"Safety and pharmacokinetics of a recombinant fusion protein linking coagulation factor VIIa with albumin in healthy volunteers","volume":"11","author":"Golor","year":"2013","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.xphs.2022.12.013_bib0016","doi-asserted-by":"crossref","first-page":"461","DOI":"10.2147\/TCRM.S205310","article-title":"Concomitant use of rFVIIa and emicizumab in people with hemophilia a with inhibitors: current perspectives and emerging clinical evidence","volume":"16","author":"Linari","year":"2020","journal-title":"Ther Clin Risk Manag"},{"key":"10.1016\/j.xphs.2022.12.013_bib0017","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1111\/j.1365-2516.2011.02674.x","article-title":"Pharmacokinetic properties of two different recombinant activated factor \u2166 formulations","volume":"18","author":"Morfini","year":"2012","journal-title":"Haemophilia"},{"key":"10.1016\/j.xphs.2022.12.013_bib0018","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1182\/blood-2009-11-254755","article-title":"Rational design of a fully active, long-acting PEGylated factor VIII for hemophilia A treatment","volume":"116","author":"Mei","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.xphs.2022.12.013_bib0019","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1038\/mt.2013.188","article-title":"Integration-deficient lentiviral vectors expressing codon-optimized R338L human FIX restore normal hemostasis in hemophilia B mice","volume":"22","author":"Suwanmanee","year":"2014","journal-title":"Mol Ther"},{"key":"10.1016\/j.xphs.2022.12.013_bib0020","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1111\/jth.13311","article-title":"An activated factor \u2166 variant with enhanced tissue factor-independent activity speeds wound healing in a mouse hemophilia B model","volume":"14","author":"Hoffman","year":"2016","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.xphs.2022.12.013_bib0021","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1182\/blood.2019000790","article-title":"CRISPR\/Cas9-mediated in vivo gene targeting corrects hemostasis in newborn and adult factor IX-knockout mice","volume":"133","author":"Wang","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.xphs.2022.12.013_bib0022","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1097\/MBC.0b013e3282e7febb","article-title":"Comparison of coagulant activity of factor VII and activated factor VII activity assays when used for determination of recombinant activated factor VII levels in plasma","volume":"18","author":"Scharling","year":"2007","journal-title":"Blood Coagul Fibrin"},{"key":"10.1016\/j.xphs.2022.12.013_bib0023","first-page":"18","article-title":"Development of quantification method for GEN-0828, a novel recombinant activated clotting factor \u2166a candidate drug, and its pharmacokinetic character istics in hemophilia B model mice","volume":"35","author":"Liu","year":"2021","journal-title":"Chin J Pharmacol Toxicol"},{"key":"10.1016\/j.xphs.2022.12.013_bib0024","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.hoc.2006.11.004","article-title":"Coagulation 2006: a modern view of hemostasis","volume":"21","author":"Hoffmann","year":"2007","journal-title":"Hematol Oncol Clin N Am"},{"key":"10.1016\/j.xphs.2022.12.013_bib0025","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1111\/jth.14644","article-title":"Enhanced potency of recombinant factor VIIa with increased affinity to activated platelets","volume":"18","author":"Enoksson","year":"2020","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.xphs.2022.12.013_bib0026","doi-asserted-by":"crossref","first-page":"351","DOI":"10.3324\/haematol.2020.248542","article-title":"Biochemical, molecular and clinical aspects of coagulation factor VII and its role in hemostasis and thrombosis","volume":"106","author":"Bernardi","year":"2021","journal-title":"Haematologica"},{"key":"10.1016\/j.xphs.2022.12.013_bib0027","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1111\/j.1365-2516.2011.02674.x","article-title":"Pharmacokinetic properties of two different recombinant activated factor VII formulations","volume":"18","author":"Morfini","year":"2012","journal-title":"Haemophilia"},{"key":"10.1016\/j.xphs.2022.12.013_bib0028","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1111\/j.1365-2516.2007.01516.x","article-title":"A randomized, double-blind trial demonstrating bioequivalence of the current recombinant activated factor VII formulation and a new robust 25[1]C stable formulation","volume":"13","author":"Bysted","year":"2007","journal-title":"Haemophilia"},{"key":"10.1016\/j.xphs.2022.12.013_bib0029","article-title":"Molecular mechanisms of inhibitor development in hemophilia","volume":"12","author":"Tieu","year":"2020","journal-title":"Mediterr J Hematol Infect Dis"},{"key":"10.1016\/j.xphs.2022.12.013_bib0030","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/j.1651-2227.2007.00199.x","article-title":"Glycosylation of therapeutic proteins in different production systems","volume":"96","author":"Werner","year":"2007","journal-title":"Acta Paediatr Suppl"},{"key":"10.1016\/j.xphs.2022.12.013_bib0031","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1186\/s12896-015-0205-1","article-title":"Differences in N-glycosylation of recombinant human coagulation factor VII derived from BHK, CHO, and HEK293 cells","volume":"15","author":"B\u00f6hm","year":"2015","journal-title":"BMC Biotechnol"},{"key":"10.1016\/j.xphs.2022.12.013_bib0032","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1111\/hae.13312","article-title":"The pharmacokinetics and pharmacodynamics of single-dose and multiple-dose recombinant activated factor VII in patients with haemophilia A or B","volume":"23","author":"Fern\u00e1ndez-Bello","year":"2017","journal-title":"Haemophilia"}],"container-title":["Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354922005809?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354922005809?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T09:40:21Z","timestamp":1758361221000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022354922005809"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":32,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["S0022354922005809"],"URL":"https:\/\/doi.org\/10.1016\/j.xphs.2022.12.013","relation":{},"ISSN":["0022-3549"],"issn-type":[{"type":"print","value":"0022-3549"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Pharmacokinetics and Pharmacodynamics of A Novel Recombinant Activated Human Factor VII, GEN-0828, in Hemophilia B Mice","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xphs.2022.12.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 American Pharmacists Association. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}